Valuation : Personalis, Inc.

Market Cap 1.82B 1.57B 1.47B 1.34B 2.53B 174B 2.54B 17.47B 6.82B 87.95B 6.84B 6.7B 292B P/E 2026 *
-15.6x
P/E 2027 * -18.1x
Enterprise Value 1.65B 1.42B 1.33B 1.21B 2.29B 157B 2.29B 15.77B 6.15B 79.39B 6.18B 6.04B 263B EV / Sales 2026 *
20x
EV / Sales 2027 * 15.7x
Free-Float
73.85%
Yield 2026 *
-
Yield 2027 * -
1 day-1.35%
1 week-2.05%
Current month+31.99%
1 month+31.99%
3 months+48.40%
6 months+92.73%
Current year+109.92%
1 week 16.55
Extreme 16.55
17.64
1 month 12.35
Extreme 12.35
18.89
Current year 4.96
Extreme 4.955
18.89
1 year 4.67
Extreme 4.6713
18.89
3 years 0.89
Extreme 0.8906
18.89
5 years 0.89
Extreme 0.8906
23.04
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 01/03/2023
Chief Executive Officer 65 30/12/2022
President 55 12/03/2026
Director TitleAgeSince
Director/Board Member 79 30/04/2019
Chairman 76 16/05/2022
Director/Board Member 72 05/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
15/07/26 Exercice

Chairperson

300,000 0.2865%
09/07/26 Exercice

Chief Executive Officer

300,000 0.2865%
29/06/26 Exercice

Chief Financial Officer

14,946 0.0143%
Change 5-day change 1-year change 3-year change Capi.($)
-1.26%-2.05%+247.40%+818.13% 1.82B
-1.01%-1.84%+1.05%+18.02% 50.47B
-2.05%-3.71%+415.38%+499.74% 44.56B
-1.01%-1.22%+39.91%+15.47% 43.08B
-2.95%-4.68%+6.78%+70.83% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.52%-5.69%+23.54%+116.37% 16.77B
+7.03%+4.65% - - 16.28B
-0.39%-1.61%+10.93%+26.81% 14.58B
-0.92%-4.02%+77.73%+38.57% 13.92B
Average -0.47%-1.96%+93.58%+183.58% 27.64B
Weighted average by Cap. -0.93%-1.25%+89.57%+125.98%

Financials

2026 *2027 *
Net sales 82.47M 71.06M 66.63M 60.82M 115M 7.88B 115M 790M 308M 3.98B 310M 303M 13.19B 110M 94.96M 89.04M 81.28M 153M 10.53B 154M 1.06B 412M 5.32B 414M 405M 17.63B
Net income -115M -99.18M -92.99M -84.89M -160M -11B -160M -1.1B -430M -5.55B -432M -423M -18.41B -102M -87.85M -82.37M -75.19M -142M -9.74B -142M -977M -381M -4.92B -383M -374M -16.31B
Net Debt -178M -153M -143M -131M -247M -16.97B -248M -1.7B -664M -8.57B -667M -652M -28.41B -91.04M -78.45M -73.55M -67.14M -126M -8.7B -127M -873M -340M -4.39B -342M -334M -14.56B
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
31/08/26 US$16.66 -2.40% 298,495
28/08/26 US$17.07 +1.61% 2,973,181
27/08/26 US$16.80 -1.64% 4,943,828
26/08/26 US$17.08 -0.99% 2,175,012
25/08/26 US$17.25 +1.11% 2,897,036
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
17.07USD
Average target price
15.44USD
Spread / Average Target
-9.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSNL Stock